NEWS

Polaris Group has entered into an agreement with the University of California,Irvine(UCI) to develop a universal influenza and coronavirus vaccine.

Polaris Group has entered into an agreement with the University of California,Irvine(UCI) to develop a universal influenza and coronavirus vaccine. This collaboration will use the mRNA vaccine technology developed in the laboratory of Dr. Philip F...

November 24, 2021

Read more >

Polaris-Press Release-FDA Response to DSMB Recommendation-5 August 2021

After consultation with FDA, Polaris will follow Data and Safety Monitoring Board’s (DSMB) recommendation to stop Phase III study in lung mesothelioma due to current success and difficulty in continued enrollment The DS...

August 05, 2021

Read more >

Polaris Phase III interim analysis of lung mesothelioma study showed a chance of greater than 80% for success at the end of study

Based on the data at the interim analysis of Feb 25, 2021, it is estimated that the chance for success, that the survival benefit of ADI PEG-20 over the control group is statistically significant at the end of the trial, will be greater than 80%. ...

March 04, 2021

Read more >

Polaris Group signs collaboration agreement with Nanotein Technologies, Inc.

Nanotein Technologies, Inc., an innovative startup biotechnology company in the San Francisco Bay Area, and Polaris Group, a developer of novel treatments for cancer, announced today they have entered into a strategic partnership to advance Nanote...

October 06, 2020

Read more >

Polaris announces to enroll the first patient of Phase IB Clinical Trial in GBM

Taipei, September 17, 2020 – Polaris Group announced today that the first patient has been dosed in a phase 1B trial of ADI‑PEG 20 in combination with Radiotherapy and Temozolomide for the treatment of Newly Diagnosed Glioblastoma Multiforme (GBM)...

September 17, 2020

Read more >

Polaris Group Announces officially secured USD $100 million new funding

Polaris Group announces closing of US$100 Million fund raising through private placement.

December 13, 2019

Read more >

Polaris Group ADI-PEG20 on the cover of AACR journals

ABOUT THE COVERPancreatic cancer is notoriously difficult to treat. One potential opportunity for targeting pancreatic cancer is through its modified amino acid metabolism. Specifically, depriving arginine-dependent tumor cells of arginine can lea...

December 10, 2019

Read more >

Polaris Group Announces Dr. Shaw Chen as New Interim CEO

SAN DIEGO, February 22, 2019 – Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer.After more than 26 years with the FDA where he was the Deputy Director in the Office of Drug Evaluat...

February 22, 2019

Read more >

Polaris Group Announces Wayne Lin as New COO

SAN DIEGO, February 22, 2019 – Polaris Group announced today that Wayne Lin, MBA has been appointed as the Chief Operating Officer.Mr. Lin brings over 20 years’ experience previously managing Cocoweb.com, as well as experience founding several sta...

February 22, 2019

Read more >

Polaris Announces Dr. Chi Van Dang Joining its Scientific Advisory Board

SAN DIEGO, July 9, 2018 — Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its Scientific Advisory Board.Best known for his pioneer work demonstrating that...

July 08, 2018

Read more >